Trial of celecoxib in amyotrophic lateral sclerosis

• Published in: Annals of neurology Vol. 60; no. 1; pp. 22 - 31
• Main Authors: Cudkowicz, Merit E., Shefner, Jeremy M., Schoenfeld, David A., Zhang, Hui, Andreasson, Katrin I., Rothstein, Jeffrey D., Drachman, Daniel B.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2006; Willey-Liss
• Subjects: Adult; Aged; Amyotrophic Lateral Sclerosis - drug therapy; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - adverse effects; Biological and medical sciences; Celecoxib; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Dinoprostone - blood; Female; Humans; Male; Medical sciences; Middle Aged; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis; Neurology; Patient Selection; Placebos; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; Treatment Outcome; Amyotrophic lateral sclerosis; Nervous system diseases; Degenerative disease; Celecoxib; Spinal cord disease; Central nervous system disease

Objective To determine whether chronic treatment with celecoxib, a cyclooxygenase‐2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS). Methods A double‐blind, placebo‐controlled, clinical trial was conducted. Three hun...